First reported late last year, Sense Biodetection has confirmed a $50m series B round backed by Cambridge Innovation Capital.
Sense Biodetection, a UK-based molecular diagnostics technology developer, has secured $50m in series B funding from investors including Cambridge Innovation Capital (CIC). Koch Disruptive Technologies (KDT), a subsidiary of chemicals and industrial group Koch Industries, led the round, which was first rumoured in November 2020. The round also featured Earlybird Health Tech Fund, a fund…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
